Adapting Biotech Leadership Across Development and Therapies
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Adapting Biotech Leadership Across Development and Therapies
-
Lu par :
-
De :
À propos de ce contenu audio
Biotech leaders are asked to do a lot; move fast, manage limited resources, and guide teams through very different stages of development. In this episode of The Emerging Biotech Leader, host Kim Kushner talks with Dr. Benit Maru, Senior Vice President at SSI Strategy, about what it really looks like to lead in that environment.
They cover:
- The contrasts between early and late development leadership, and why those transitions can feel like two different roles
- How scenario planning and structured conversations help teams prepare for uncertainty
- Why documents like the clinical development plan or target product profile should be seen as living tools, not paper exercises
- The similarities and differences in leading across modalities—devices, biologics, and advanced therapies like cell and gene
- The importance of team dynamics, culture, and knowing when to bring in outside expertise
This episode is full of practical takeaways for biotech leaders who want to keep their strategies sound, their teams aligned, and their programs moving forward under pressure.
Aucun commentaire pour le moment
